Benchmark sell vaccine manufacturing assets to CGT Catapult

Benchmark Holdings has sold its vaccine manufacturing facility and business to the Cell and Gene Therapy Catapult (CGT Catapult) for £16 million to aid the battle against COVID-19.

The sale follows Sheffield-based Benchmark’s review of its vaccine strategy earlier this year. The aim was to determine the best route to deliver a return from its investment in this business to date.

The sale comes as the government looks to build infrastructure in the UK to scale the manufacture of vaccines and therapeutics in support of the response to COVID-19 created a perfect solution to ensure that our vaccine manufacturing facility is put to best use and to secure employment for its workforce.

Benchmark’s Braintree-based vaccine manufacturing facility and team have a wide range of GMP accredited capabilities including antigen production, formulation, process development and scale manufacturing and can be rapidly repurposed to produce human vaccines.

The state-of-the-art facility, which was completed in 2017, employs 75 highly qualified staff who will transfer to CGT Catapult on completion of the sale.

The transaction is a significant milestone in Benchmark’s strategy to reduce its cost base and focus on its core areas to achieve profitability.

The proceeds do not represent a profit to Benchmark, but the company said are based on the facility’s asset value and have been agreed to support the Government’s vaccine strategy.

The proceeds will further strengthen the Group’s financial position and liquidity, with total potential consideration from recent disposals, including this sale, of c.£42 million.

“I am very pleased to announce this transaction which is another significant step forward in our strategy of becoming a streamlined, profitable business focused on our key areas of competency,” said Benchmark CEO Trond Williksen.

“Benchmark is also delighted that the timing and conclusion of our vaccine strategy review coincides with the need to scale capabilities to manufacture human vaccines in response to COVID-19 and that the talented team at Benchmark will become part of this critical effort.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Blenrep becomes first anti-BCMA approved globally

GlaxoSmithKline (GSK) has secured US approval for Blenrep (belantamab mafodotin-blmf) as a monotherapy treatment for adult patients with relapsed or refractory multiple myeloma. This indication...

Joint investment sees UK gov secure pipeline of coronavirus vaccine candidate

The UK government and biotech Valneva have jointly invested in a Scottish facility to bolster vaccine manufacturing capacity. The multi-million-pound investment will allow the government...

Redx out-licenses porcupine inhibitor to AstraZeneca

UK drug discovery and development company, Redx Pharma, has signed a significant out-licensing agreement for its porcupine inhibitor, RXC006, with AstraZeneca. AstraZeneca will take RXC006...

New Chief Medical Officer for Valneva

Valneva, a specialty vaccine company based in France, has appointed Juan Carlos Jaramillo, as Chief Medical Officer and member of the Management Board. Starting 1st...

Majority of top pharma firms report YoY growth in 2019 – data

In 2019, 17 of the top twenty major pharmaceutical players reported year-on-year revenue growth, according to GlobalData. “One winner was Takeda, which saw more than...

Related news

ACG promotes Susheel Pillai as the new CEO for Inspection Business

ACG, a leading supplier of fully integrated solutions to the global pharmaceutical and nutraceutical industry, today announced the promotion of Susheel Pillai as the new...

Blenrep becomes first anti-BCMA approved globally

GlaxoSmithKline (GSK) has secured US approval for Blenrep (belantamab mafodotin-blmf) as a monotherapy treatment for adult patients with relapsed or refractory multiple myeloma. This indication...

Joint investment sees UK gov secure pipeline of coronavirus vaccine candidate

The UK government and biotech Valneva have jointly invested in a Scottish facility to bolster vaccine manufacturing capacity. The multi-million-pound investment will allow the government...

Redx out-licenses porcupine inhibitor to AstraZeneca

UK drug discovery and development company, Redx Pharma, has signed a significant out-licensing agreement for its porcupine inhibitor, RXC006, with AstraZeneca. AstraZeneca will take RXC006...